A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy

NCT07728955 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer ( SCLC )

Interventions

DRUG: benmelstobart in combination with anlotinib and etoposide

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University